Aims : We presented our clinical experience that the product- switching, population pharmacokinetics, and the clinical experience of rFVIII- Fc for previously- treated patients (PTP) with hemophilia A. Methods : From Novmber, 2018 to February, 2019, there were to-tally 35 severe- type PTP with hemophilia A enrolled, five boys and 30 adults, who switched from rFVIII to rFVIII- Fc at Taipei Medical University Hospital. Pharmacokinetics(PK) study was performed from 3 to 5 spots of blood sampling and the individual half life was calculated through the WAPPS website. Other clinical data were also collected and analyzed.
|頁（從 - 到）||297|
|期刊||Research and Practice in Thrombosis and Haemostasis|
|出版狀態||已發佈 - 6月 2019|